Health Condition 1: K859- Acute pancreatitis, unspecified
Conditions
Interventions
Intervention1: Buprenorphine: Buprenorphine 0.3 mg intravenous 8 hourly for 40 hours
Control Intervention1: Diclofenac: Diclofenac 75 mg Intravenous 8 hourly for 40 hours
Control Intervention2: Fentan
Sponsors
Mayank Saini
Eligibility
Inclusion criteria
Inclusion criteria: Acute pancreatitis as defined by the clinical symptoms, elevation in serum amylase level(more than three times the upper limit of normal range) or imaging finding Abdominal pain at the time of enrolment Patients who have presented to the hospital within the first 5 days after onset of pain.
Exclusion criteria
Exclusion criteria: Pregnancy Patients of acute pancreatitis who have renal failure (Serum Creatinine > 1.5 mg/dl) at presentation Patients who were contraindicated to Opioids and NSAIDS Who already take Opioids and NSAIDS for other reasons Patients with history of coronary artery disease Patients with altered mental status Patients with imaging evidence of chronic pancreatitis Patients requiring ventilatory support
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Difference in the dose of fentanyl required in diclofenac and buprenorphine group 2. Difference in the number of effective and ineffective demands in diclofenac and buprenorphine group Timepoint: 24 hours, 48 hours, 72 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Difference in the pain free interval in diclofenac and buprenorphine groupTimepoint: 24, 48 and 72 hours ;Difference in the mean VAS score in the diclofenac and buprenorphine groupTimepoint: 24, 48 and 72 hours;The development of organ failure, assessed using the Marshall scoringTimepoint: 72 hours;The difference in the adverse events between the 2 groupsTimepoint: 72 hours | — |
Countries
India
Contacts
Public ContactJayanta Samanta
PGIMER, Chandigarh
Outcome results
None listed